Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic and orthopedic markets. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic or orthopedic industry newsletters.

Ophthalmic Orthopedic

Recently Added ophthalmic

3/27/2020
BreakingCOVID 19MeetingOphthalmic
Market Scope Lists 2020 Ophthalmic Meetings Canceled, Delayed Due to COVID-19

Market Scope is tracking the status of 2020 ophthalmic meetings worldwide as the COVID-19 outbreak spreads. Several conferences have been delayed or canceled outright. Here is the latest informatio...

3/27/2020
BreakingCOVID 19DiagnosticOphthalmicRetina
COVID-19 Update: MDR Delay Coming?; Glaucoma Meeting Postponed; Companies Join Pandemic Fight

The European Commission (EC) is working on a proposal to delay enforcement of the EU Medical Device Regulation by a year, a spokesperson said March 25. Policymakers hope to submit the proposal in e...

3/27/2020
BreakingCornealDeviceOphthalmic
Surgeon, LinkoCare Developing Corneal Inlay Made of Biosynthetic Collagen

Pavel Stodulka, MD, PhD, of the Czech Republic, is working with Swedish companyLinkoCare to develop a corneal reshaping inlay made of biosynthetic collagen to correct presbyopia. The inlay candidat...

3/27/2020
BreakingDeviceLow VisionOphthalmicRegulation
Second Sight Gains CE Marking, US Conditional Approval for Wearables to be Tested with Orion

Second Sight announced March 19 that it had gained CE marking and US conditional approval for its next-generation wearables with the Argus II retinal prosthesis that include a more powerful video p...

3/27/2020
BreakingDealsOphthalmicPharmaRetina
Ribomic Licenses Wet AMD Candidate to Aju Pharm

Tokyo-based Ribomic reported March 17 that it had licensed to Aju Pharm a retinal candidate (RBM-007) for wet age-related macular degeneration (wet AMD) in Korea and Southeast Asia. Aju, of South K...

3/27/2020
BreakingOphthalmicPharmaRetina
Iveric bio Appoints Dugel as Executive Vice President and Chief Strategy and Business Officer

Iveric bio announced March 23 that leading retina specialist Pravin Dugel, MD, would be appointed executive vice president and chief strategy and business officer, effective April 1. The New York c...

3/27/2020
BreakingDeviceLow VisionOphthalmic
McGuire Steps Down as CEO of Second Sight; Chairman Williams Takes Over as Interim Chief

Second Sight Medical Products CEO Will McGuire is leaving the company to accept a similar role at Ra Medical, a Carlsbad, California, medical device company focusing on commercializing excimer lase...

3/27/2020
BreakingIOLOphthalmicRegulation
Lenstec Submits PMA Application to FDA for SBL-3 Segmented Bifocal Lens

Lenstec announced March 16 that had submitted a premarket approval application to the US FDA for its SBL-3 presbyopia-correcting intraocular lens (PC-IOL). The SBL-3 would be the first segmented bi...

3/27/2020
BreakingDealsGene TherapyOphthalmicRetina
Horama Licenses Retinal Gene Therapy Candidate from Leiden University

French ophthalmic gene therapy company Horama announced March 18 that it licensed from Leiden University Medical Center an adeno-associated viral (AAV) gene therapy program to treat inherited retin...

3/27/2020
BreakingClinical TrialOphthalmicPharmaRetina
Graybug Ends Phase IIb Enrollment Early After Confirming Dosing Regimen

Graybug Vision announced March 18 that it had closed enrollment early in its Phase IIb trial of GB-102 (1 or 2 mg) in wet age-related macular degeneration (AMD), because the company intends to move...

3/27/2020
BreakingCornealFundingOphthalmicPharma
Eyenovia Raises $5.3 Million in Private Placement for Microdose Candidates

Eyenovia reported March 25 that it raised $5.3 million in net proceeds in a private placement of units made up of common stock and warrants. The company said it intends to use the proceeds, togethe...

3/24/2020
BreakingCOVID 19DiagnosticEarningsMeetingOphthalmic
COVID-19 Update: OCTANe Summit, AAPOS Meeting, Industry Announcements

OCTANe has moved its Ophthalmology Technology Summit to July 31 from June 26 due to the pandemic, the group announced on its website. The Fashion Island Hotel in Newport Beach, California, remains ...

Past News Stories

3/20/2020
BreakingDry EyeGlaucomaOphthalmic
Sight Sciences Raises More than $30 Million in Series E Round

Sight Sciences announced March 18 that it closed a Series E preferred stock financing round of more than $30 million. The Menlo Park, California, company said proceeds will be used for continued cl...

3/20/2020
BreakingCataractOphthalmicSurgical
Alcon Launches Vivity PC-IOL in Select European Countries

Alcon announced March 12 that it launched its Vivity presbyopia-correcting intraocular lens (PC-IOL) in select European countries, with additional market launches coming throughout 2020. The eye ca...

3/20/2020
BreakingOphthalmicPharmaRetinaStudy
Disappointing Phase IIa Results Lead Santen, TRACON to Scrap DE-122 for Wet AMD

Santen Pharmaceutical, of Japan, and TRACON Pharmaceuticals, of San Diego, announced March 9 that they had discontinued the development of DE-122 (carotuximab) for the treatment of wet age-related ...

3/20/2020
BreakingCOVID 19MeetingOphthalmic
COVID-19 Update: Kiawah Eye Meeting Delayed; Novartis Donates 130 million Doses of Drug for Pandemic

The organizers of the 2020 Kiawah Eye meeting have rescheduled it for Sept. 10-12, 2020, at the Kiawah Island Resort in South Carolina. “These next few weeks remain uncertain at this time, and we f...

3/20/2020
BreakingCataractOphthalmicSurgical
Rayner Surgical Group for Sale, UK News Outlets Report

Rayner Surgical Group, the only British manufacturer of intraocular lenses, is for sale for £300 million to £400 million, according to UK news outlets. The Daily Mail reported March 7 that buyout s...

3/20/2020
BreakingDealsOphthalmicRetina
Clearside Licenses Xipere to Arctic Vision for Greater China and South Korea

Clearside Biomedical announced March 11 that Arctic Vision, of China, had acquired an exclusive license for the development and commercialization of Xipere (triamcinolone acetonide suprachoroidal i...

3/20/2020
BreakingEarningsOphthalmicPharma
Harrow Health Reports 2019 Net Revenue of $51.2 Million

Harrow Health reported March 13 that full year 2019 consolidated net revenue totaled $51.2 million, a 23.7 percent increase over 2018 revenue of $41.4 million. Q4-2019 net revenue was $12.6 million...

3/20/2020
BreakingDealsOphthalmic
Everads Therapy Licenses Suprachoroidal Delivery System to Global Pharma Company

Everads Therapy, of Israel, announced March 12 that it had licensed its suprachoroidal delivery system to a global pharmaceutical company. The deal was Everads’ first commercial agreement. Under th...

3/20/2020
BreakingCataractEarningsOphthalmicSurgical
Omeros Reports Full Year 2019 Revenue of $111.8 Million

Omeros announced March 2 that its full year 2019 revenue was $111.8 million, a 274 percent increase from $29.9 million for full year 2018. The Seattle-based developer of Omidria said the significan...

3/19/2020
BreakingOphthalmicSurgical
COVID-19 Update: AAO Advises Only Urgent Surgery, ASCRS Cancels Meeting

The American Academy of Ophthalmology announced March 18 that it is now “essential that all ophthalmologists cease providing any treatment other than urgent or emergent care immediately” to reduce ...

3/17/2020
EarningsNewsletterOphthalmicPharmaSurgery
Ophthalmic Company Revenue Increases 6.8 Percent in Fourth Quarter of 2019

Overall ophthalmic revenue in Q4-2019 totaled $9.8 billion, an increase of 6.8 percent over the same quarter last year. The total included Market Scope estimates for private companies and excluded ...

3/17/2020
NewsletterOphthalmicPharmaRetina
Oculis Reaches for ‘Holy Grail’ of Topical Retinal Medication

Retina specialist Pravin Dugel, MD, told Market Scope in a phone interview March 5 that Swiss company Oculis is approaching “the holy grail for topical technologies.” A Phase II study, DX-211, demo...

Want to Read the Full Article?

Register A Corporate Account

A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.

Select one or more
Select one or more

Market Scope

13421 Manchester Road, Suite 201 | St. Louis, MO 63131 | Phone: 314-835-0600 | Email: info@market-scope.com

©2020 Market Scope, LLC. All Rights reserved.